Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Drops By 14.8%

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) saw a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 148,200 shares, a decrease of 14.8% from the November 15th total of 173,900 shares. Based on an average daily volume of 90,200 shares, the days-to-cover ratio is currently 1.6 days. Approximately 3.0% of the company’s stock are short sold.

Institutional Trading of Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Armistice Capital LLC bought a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the second quarter, according to the company in its most recent disclosure with the SEC. The fund bought 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned 11.30% of Brainstorm Cell Therapeutics at the end of the most recent quarter. 14.33% of the stock is currently owned by institutional investors.

Brainstorm Cell Therapeutics Trading Down 4.0 %

BCLI traded down $0.06 during trading on Friday, hitting $1.45. 46,458 shares of the company’s stock traded hands, compared to its average volume of 61,048. The stock has a market capitalization of $8.27 million, a price-to-earnings ratio of -0.30 and a beta of 0.36. The company’s 50 day simple moving average is $1.71 and its two-hundred day simple moving average is $3.91. Brainstorm Cell Therapeutics has a 12-month low of $1.05 and a 12-month high of $11.89.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of Brainstorm Cell Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.